Astellas Pharma's market cap is currently $2.70T. The company's EPS TTM is ¥30.596; its P/E ratio is 49.09; and it has a dividend yield of 5.13%. Astellas Pharma is scheduled to report earnings on February 4, 2025, and the estimated EPS forecast is ¥24.52. See an overview of income statement, balance sheet, and cash flow financials.

	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
Income Statement
Total Revenue	¥ 1.60T	¥ 1.52T	¥ 1.30T	¥ 1.25T	¥ 1.30T
Gross Profit	¥ 1.21T	¥ 1.23T	¥ 1.04T	¥ 1.00T	¥ 1.02T
Operating Income	¥ 124.61B	¥ 133.03B	¥ 155.69B	¥ 136.05B	¥ 243.99B
EBITDA	¥ 195.34B	¥ 240.46B	¥ 241.03B	¥ 219.83B	¥ 316.41B
Net Income	¥ 17.05B	¥ 98.71B	¥ 124.09B	¥ 120.59B	¥ 195.41B
Balance Sheet
Cash & Short-Term Investments	¥ 335.69B	¥ 396.62B	¥ 337.28B	¥ 331.69B	¥ 327.85B
Total Assets	¥ 3.57T	¥ 2.46T	¥ 2.33T	¥ 2.27T	¥ 2.32T
Total Debt	¥ 1.01T	¥ 200.01B	¥ 212.74B	¥ 278.26B	¥ 413.33B
Net Debt	¥ 670.03B	¥ -176.83B	¥ -103.24B	¥ -47.86B	¥ 94.94B
Total Liabilities	¥ 1.97T	¥ 948.56B	¥ 872.09B	¥ 887.51B	¥ 1.03T
Stockholders' Equity	¥ 1.60T	¥ 1.51T	¥ 1.46T	¥ 1.39T	¥ 1.29T
Cash Flow
Free Cash Flow	¥ 89.98B	¥ 239.23B	¥ 181.00B	¥ 229.40B	¥ 144.11B
Operating Cash Flow	¥ 172.47B	¥ 327.77B	¥ 257.44B	¥ 306.84B	¥ 222.00B
Investing Cash Flow	¥ -845.80B	¥ -84.50B	¥ -62.41B	¥ -81.89B	¥ -389.79B
Financing Cash Flow	¥ 614.06B	¥ -195.62B	¥ -216.30B	¥ -229.48B	¥ 181.06B

Currency in JPY

Astellas Pharma Earnings and Revenue History

Income Statement >

Astellas Pharma Debt to Assets

Balance Sheet >

Astellas Pharma Cash Flow

Cash Flow >

Astellas Pharma Forecast EPS vs Actual EPS

Earnings >

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing